绽妍生物拟北交所上市：70后副总王昆操作员出身，曾是董事长同事

Company Overview - Zhan Yan Biotechnology Co., Ltd. was established on December 6, 2019, with a registered capital of 61.62 million yuan and is located in Chengdu, Sichuan, China [1] - The company is primarily engaged in the research, production, and sales of biomedical materials, dermatological skincare products, and bioactive raw materials [1] - The controlling shareholder is Zhang Yingting, who directly holds 62.1551% of the company's shares [1] IPO and Financial Performance - Zhan Yan Biotechnology has completed its IPO counseling registration with the Sichuan Securities Regulatory Bureau and plans to list on the Beijing Stock Exchange [1] - The company aims to be listed on the New Third Board by September 2025 [1] - Projected revenues for 2023 and 2024 are 486 million yuan and 597 million yuan, respectively, with net profits of 68.48 million yuan and 73.50 million yuan [2][3] - The gross profit margins for 2023 and 2024 are expected to be 62.33% and 68.34%, respectively [2][3] Shareholding Structure - As of the date of the public transfer prospectus, Zhang Yingting directly holds 62.16% of the shares and, through concerted actions, controls 91.22% of the voting rights [3] - Other shareholders include Yang Fengle, who holds 17.79%, and Hengqin Zhan Yan, an employee stock ownership platform, which holds 11.28% [3] - Wang Kun directly holds 4.06% and indirectly holds 0.24%, while Tax Ke Ying directly holds 0.41% and indirectly holds 0.31% [4] Management Team - Zhang Yingting serves as the Chairman and Manager of the company [5] - Wang Kun is the Director and Deputy Manager, while Tax Ke Ying is the Secretary of the Board and Chief Financial Officer [5] - The management team has extensive experience in the pharmaceutical and biotechnology sectors, with backgrounds in various companies prior to joining Zhan Yan Biotechnology [6][7][8]